Evaxion Biotech (NASDAQ: EVAX) reported Q1 EPS of ($0.23), $0.07 better than the analyst estimate of ($0.30).

Lars Wegner, CEO of Evaxion, said: “Evaxion made strong progress in Q1 2021, successfully concluding our U.S. IPO and continuing to advance our clinical programs. Our two lead product candidates, EVX-01 and EVX-02, are on track for results from Phase 1/2a trials late in Q2 and we continue to develop our RAVEN AI platform for vaccine design and development for viral infections. We believe that our cash reserves of $27 million provide a solid financial foundation and will facilitate the continued development of our four lead programs.”

For earnings history and earnings-related data on Evaxion Biotech (EVAX) click here.